Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iseganan HCl for Oral Mucositis in Head and Neck Cancer Radiotherapy
NCT00022373Phase 3Unknown
- Sponsor
- National Cancer Institute
- Start
- Dec 2000
- Modality
- Recombinant Proteins and Enzymes, Antimicrobial Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in oral mucositis (OM) comparing Iseganan HCl, Placebo and Standard of Care (3 arms). Primary endpoint: Severity of Oral Mucositis at day 56. Status: unknown.
02
Drugs
iseganan
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT00022373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022373.